Juvenescence Announces Licensing Agreement with Evgen Pharma plc
Retrieved on:
Tuesday, September 15, 2020
Juvenescence Limited (Juvenescence), a life sciences company focused on modifying aging and increasing human healthspan, announced today a partnership with Evgen Pharma plc to license its sulforaphane stabilization technology for use in several non-pharmaceutical applications led by its JuvLife division.
Key Points:
- Juvenescence Limited (Juvenescence), a life sciences company focused on modifying aging and increasing human healthspan, announced today a partnership with Evgen Pharma plc to license its sulforaphane stabilization technology for use in several non-pharmaceutical applications led by its JuvLife division.
- Juvenescence is based on a new understanding of the underlying biological causes of aging, creating evidence-based and science-backed therapies.
- It is focused on increasing how long people live in health by preventing the diseases of aging in the first place.
- Evgen will receive upfront and milestone payments of up to $10.5m, and in addition, royalties on sales of the commercialized product.